Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
for ophthalmic disease, today announced the appointment of Ramin Valian as Chief Executive Officer. A veteran biopharmaceutical executive, Valian brings more than 20 years of global commercial and strategic leadership in eye care, with expertise spanning corneal disease, surgical and interventional glaucoma, retina, and consumer eye care. He has successfully led the launch of six ophthalmic products across therapeutics and medical technologies. Valian joins Emmecell following a distinguished career at Allergan and AbbVie, where he played key roles in global strategy, clinical development, and commercialization of high-impact ophthalmic products. His decision to join Emmecell underscores his confidence in the company's science, platform, and potential to deliver meaningful clinical impact for patients. "I believe Emmecell's magnetic cell delivery technology has the potential to fundamentally redefine ophthalmic treatment—from corneal disease to geographic atrophy," said Ramin Valia
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)PR Newswire
- Five Takeaways From The 2026 J.P. Morgan Healthcare Conference [Forbes]Forbes
- AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains [Yahoo! Finance]Yahoo! Finance
- AbbVie (NYSE:ABBV) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.MarketBeat
- Top Research Reports for AbbVie, Intel & Boeing [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 1/7/26 - Form 8-K
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- ABBV's page on the SEC website